Is Davunetide FDA approved?

Davunetide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Davunetide administered in research settings?

In research settings, Davunetide is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is Dihexa administered in research settings?

In research settings, Dihexa is typically administered via the oral, transdermal, or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Davunetide vs Dihexa

Peptide Comparison

Davunetide vs Dihexa

Q: What is the difference between Davunetide and Dihexa?

Davunetide: Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation. Dihexa: HGF/MET receptor potentiator; promotes new synapse formation; estimated 7 orders of magnitude more potent than BDNF in synaptogenesis models

Both are Neuro & Cognitive peptides.

Davunetide

NAP

CognitiveInvestigationalResearch Only

No providers listed yet

Full Davunetide profile →

Dihexa

PNB-0408

CognitiveResearch Only

Half-life: Unknown (likely days based on effects)

49 providers listed

Full Dihexa profile →

Bottom line

Davunetide carries stronger published evidence (RCT, 3 key studies) than Dihexa (Review, 2); both are research compounds.

Quick Verdict

Davunetide

Evidence

Clinical

Dihexa

Evidence

Preclinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Davunetide
Further along in FDA review	Davunetide
Oral administration option	Dihexa
More provider options (0 vs 49)	Dihexa

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Davunetide

Dihexa

Mechanism Family

Neuro & Cognitive

Half-life

—

Unknown (likely days based on effects)

FDA Status

investigational

nomination withdrawn

Admin Routes

intranasal, subcutaneous

oral, transdermal, subcutaneous

Availability

Research Only

Providers

None listed

49 listed

Avail. Notes

—

Angiotensin IV-derived hexapeptide (PNB-0408) from WSU research. Cognitive enhancement in animal models. No FDA approval, no NDA or IND. Not on any FDA list. Research compound only.

Research Evidence

Davunetide

ClinicalRCT · 3 key studies · most recent 2026

Dihexa

PreclinicalReview · 2 key studies · dated evidence base — most recent 2002

Research Citations

Davunetide

Cohort2026 · Epilepsy Res

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

RCT2013 · Neuropsychopharmacology

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…

RCT2011 · Schizophrenia Research

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…

Dihexa

Review2002 · Neuroscience and Biobehavioral Reviews

Neural plasticity and the brain renin-angiotensin system

Animal2001 · Peptides

Angiotensin IV enhances LTP in rat dentate gyrus in vivo

About Davunetide

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Research Areas

neuroprotectiontau stabilizationcognitive enhancementmemorysynaptic plasticity

About Dihexa

HGF/MET receptor potentiator; promotes new synapse formation; estimated 7 orders of magnitude more potent than BDNF in synaptogenesis models

Research Areas

HGF/MET receptor potentiation supporting synaptogenesishippocampal LTP enhancement in preclinical modelsmemory and neuroplasticity support (rodent data)no established human safety or pharmacokinetic profile

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Davunetide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Dihexa

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Find Providers

Where to source these peptides

Providers offering

Davunetide

Browse directory →

Providers offering

Dihexa

49 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.